ARTICLE | Company News
WuXi, ABL expand deal to develop bispecifics
March 1, 2019 7:31 PM UTC
WuXi Biologics Inc. (HKSE:2269) granted ABL Bio Inc. (KOSDAQ:298380) rights to use WuXi's WuXiBody and CD3 platforms to develop and commercialize bispecific antibodies targeting an undisclosed immune checkpoint receptor.
The partners said the deal expands an exclusive November license granting ABL rights to the platforms to develop and manufacture multiple other bispecific antibodies...